1
|
Traoré L, Savadogo M, Zouré AA, Kiendrebeogo TI, Soudre FMBTB, Dabre S, Traore ADD, Adico MDW, Lare T, Ouedraogo TWC, Ouedraogo RA, Ouattara AK, Yelemkoure ET, Sawadogo AY, Zongo N, Bambara HA, Nadembega CW, Djigma FW, Simpore J. Carrying SNP rs17506395 (T > G) in TP63 gene and CCR5Δ32 mutation associated with the occurrence of breast cancer in Burkina Faso. Open Life Sci 2024; 19:20220847. [PMID: 38585642 PMCID: PMC10998675 DOI: 10.1515/biol-2022-0847] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/22/2023] [Revised: 01/25/2024] [Accepted: 03/05/2024] [Indexed: 04/09/2024] Open
Abstract
Genetic alterations in the TP63 (GenBank: NC_000003.12, ID: 8626) and CCR5 (receptor 5 chemokine co-receptor) (GenBank: NC_000003.12, ID: 1234) genes may increase the risk of developing breast cancer. The aim of this study was to investigate the probable involvement of polymorphisms rs17506395 in the TP63 (tumour protein 63) gene and the CCR5Δ32 mutation in the occurrence of breast cancer in Burkina Faso. This case-control study included 72 patients and 72 controls. Genotyping of SNP rs17506395 (TP63) was performed by polymerase chain reaction-restriction fragment length polymorphism, and genotyping of the CCR5Δ32 mutation was performed by allele-specific oligonucleotide polymerase chain reaction. For SNP rs17506395 (TP63), the genotypic frequencies of wild-type homozygotes (TT) and heterozygotes (TG) were, respectively, 27.72 and 72.22% in cases and 36.11 and 63.89% in controls. No mutated homozygotes (GG) were observed. For the CCR5Δ32 mutation, the genotypic frequencies of wild-type homozygotes (WT/WT) and heterozygotes (WT/Δ32) were 87.5 and 13.5%, respectively, in the cases and 89.29 and 10.71%, respectively, in the controls. No mutated homozygotes (Δ32/Δ32) were observed. None of the polymorphisms rs17506395 of the TP63 gene (OR = 1.47, 95% CI = 0.69-3.17, P = 0.284) and the CCR5Δ32 mutation (OR = 1.32, 95% CI = 0.46-3.77; P = 0.79) were associated with the occurrence of breast cancer in this study.
Collapse
Affiliation(s)
- Lassina Traoré
- Laboratory of Molecular and Genetic Biology (LABIOGENE), Joseph KI-ZERBO University, 03 BP 7021, Ouagadougou 03, Burkina Faso
- Pietro Annigoni Biomolecular Research Centre (CERBA), 01 BP 364, Ouagadougou 01, Burkina Faso
| | - Mousso Savadogo
- Laboratory of Molecular and Genetic Biology (LABIOGENE), Joseph KI-ZERBO University, 03 BP 7021, Ouagadougou 03, Burkina Faso
- Pietro Annigoni Biomolecular Research Centre (CERBA), 01 BP 364, Ouagadougou 01, Burkina Faso
| | - Abdou Azaque Zouré
- Laboratory of Molecular and Genetic Biology (LABIOGENE), Joseph KI-ZERBO University, 03 BP 7021, Ouagadougou 03, Burkina Faso
- Pietro Annigoni Biomolecular Research Centre (CERBA), 01 BP 364, Ouagadougou 01, Burkina Faso
- Biomedical Research Laboratory (LaReBio), Biomedical and Public Health Department, Health Sciences Research Institute (IRSS/CNRST), 03 BP 7192Ouaga 03, Burkina Faso
| | - Touwendpoulimdé Isabelle Kiendrebeogo
- Laboratory of Molecular and Genetic Biology (LABIOGENE), Joseph KI-ZERBO University, 03 BP 7021, Ouagadougou 03, Burkina Faso
- Pietro Annigoni Biomolecular Research Centre (CERBA), 01 BP 364, Ouagadougou 01, Burkina Faso
| | - Fabienne Marie B. T. B. Soudre
- Laboratory of Molecular and Genetic Biology (LABIOGENE), Joseph KI-ZERBO University, 03 BP 7021, Ouagadougou 03, Burkina Faso
- Laboratory Department, University Hospital Centre-Yalgado OUEDRAOGO, Joseph KI-ZERBO University, UFR/SDS, 03 BP 7021, Ouagadougou 03, Ouagadougou, Burkina Faso
| | - Soayebo Dabre
- Laboratory of Molecular and Genetic Biology (LABIOGENE), Joseph KI-ZERBO University, 03 BP 7021, Ouagadougou 03, Burkina Faso
- Pietro Annigoni Biomolecular Research Centre (CERBA), 01 BP 364, Ouagadougou 01, Burkina Faso
| | - Aida Djé Djénéba Traore
- Laboratory of Molecular and Genetic Biology (LABIOGENE), Joseph KI-ZERBO University, 03 BP 7021, Ouagadougou 03, Burkina Faso
- Pietro Annigoni Biomolecular Research Centre (CERBA), 01 BP 364, Ouagadougou 01, Burkina Faso
| | - Marc Donald Wilfried Adico
- Laboratory of Molecular and Genetic Biology (LABIOGENE), Joseph KI-ZERBO University, 03 BP 7021, Ouagadougou 03, Burkina Faso
- Pietro Annigoni Biomolecular Research Centre (CERBA), 01 BP 364, Ouagadougou 01, Burkina Faso
| | - Tilate Lare
- Laboratory of Molecular and Genetic Biology (LABIOGENE), Joseph KI-ZERBO University, 03 BP 7021, Ouagadougou 03, Burkina Faso
- Pietro Annigoni Biomolecular Research Centre (CERBA), 01 BP 364, Ouagadougou 01, Burkina Faso
| | - Teega-Wendé Clarisse Ouedraogo
- Laboratory of Molecular and Genetic Biology (LABIOGENE), Joseph KI-ZERBO University, 03 BP 7021, Ouagadougou 03, Burkina Faso
- Pietro Annigoni Biomolecular Research Centre (CERBA), 01 BP 364, Ouagadougou 01, Burkina Faso
| | - Rogomenoma Alice Ouedraogo
- Laboratory of Molecular and Genetic Biology (LABIOGENE), Joseph KI-ZERBO University, 03 BP 7021, Ouagadougou 03, Burkina Faso
- Pietro Annigoni Biomolecular Research Centre (CERBA), 01 BP 364, Ouagadougou 01, Burkina Faso
- Gaoua University Centre, NAZI BONI University, 01 BP 1091, Bobo-Dioulasso 01, Burkina Faso
| | - Abdoul Karim Ouattara
- Laboratory of Molecular and Genetic Biology (LABIOGENE), Joseph KI-ZERBO University, 03 BP 7021, Ouagadougou 03, Burkina Faso
- Pietro Annigoni Biomolecular Research Centre (CERBA), 01 BP 364, Ouagadougou 01, Burkina Faso
- Manga University Centre, Norbert ZONGO University, Koudougou, Burkina Faso
| | - Edwige T. Yelemkoure
- Laboratory of Molecular and Genetic Biology (LABIOGENE), Joseph KI-ZERBO University, 03 BP 7021, Ouagadougou 03, Burkina Faso
- Pietro Annigoni Biomolecular Research Centre (CERBA), 01 BP 364, Ouagadougou 01, Burkina Faso
| | - Alexis Yobi Sawadogo
- Gynecology Department, Yalgado Ouédraogo University Hospital, UFR/SDS, 03 BP 7021, Ouagadougou 03, Ouagadougou, Burkina Faso
| | - Nayi Zongo
- Department of Surgery, Visceral and Digestive Surgery Service, Yalgado Ouédraogo University Hospital, Joseph KI-ZERBO University, UFR/SDS 03 BP 7021, Ouagadougou 03, Ouagadougou, Burkina Faso
| | - Hierrhum Aboubacar Bambara
- Oncology Department, University Hospital Centre-BOGODOGO, Joseph KI-ZERBO University, UFR/SDS, 03 BP 7021, Ouagadougou 03, Ouagadougou, Burkina Faso
| | - Christelle W. Nadembega
- Laboratory of Molecular and Genetic Biology (LABIOGENE), Joseph KI-ZERBO University, 03 BP 7021, Ouagadougou 03, Burkina Faso
- Pietro Annigoni Biomolecular Research Centre (CERBA), 01 BP 364, Ouagadougou 01, Burkina Faso
| | - Florencia W. Djigma
- Laboratory of Molecular and Genetic Biology (LABIOGENE), Joseph KI-ZERBO University, 03 BP 7021, Ouagadougou 03, Burkina Faso
- Pietro Annigoni Biomolecular Research Centre (CERBA), 01 BP 364, Ouagadougou 01, Burkina Faso
| | - Jacques Simpore
- Laboratory of Molecular and Genetic Biology (LABIOGENE), Joseph KI-ZERBO University, 03 BP 7021, Ouagadougou 03, Burkina Faso
- Pietro Annigoni Biomolecular Research Centre (CERBA), 01 BP 364, Ouagadougou 01, Burkina Faso
| |
Collapse
|
2
|
Kiendrebeogo IT, Zoure AA, Zongo FI, Ouedraogo SY, Sawadogo AY, Amegnona J, Sombie HK, Bazie JTVE, Sorgho PA, Yonli AT, Ouedraogo MNL, Obiri-Yeboah D, Zongo N, Bambara HA, Simpore J. Screening of BRCA1 (c.5177_5180delGAAA rs80357867 and c.4986+6T>C rs80358086) and the BRCA2 (c.6445_6446delAT rs80359592) Genes for Breast Cancer Prevention in Burkina Faso. Ethiop J Health Sci 2022; 32:699-708. [PMID: 35950060 PMCID: PMC9341024 DOI: 10.4314/ejhs.v32i4.5] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/16/2022] [Accepted: 04/12/2022] [Indexed: 11/17/2022] Open
Abstract
Background The objective of this study is to search for mutations in the BRCA1 (c.5177_5180delGAAA and c.4986+6T>C) and BRCA2 genes (c.6445_6446delAT) in a population of women diagnosed with breast cancer. Methods This is a case-control study that involved 140 participants, including 70 patients with histologically diagnosed breast cancer and 70 healthy women without breast cancer. Mutations in the BRCA1 (rs80357867, rs80358086) and BRCA2 (rs80359592) genes were tested by real-time PCR. The 95% confidence interval Odds Ratio (OR) was used to estimate the associations between specific genotypes and breast cancer. Results The study revealed that no mutations were detected for rs80359592. Similarly, no reference allele (TTTC/TTTC) of rs80357867 was found in this study. However, the homozygous double mutant (-/) genotype of this rs80357867 was observed in 11.43% and 1.43% of patients and controls respectively, while 88.57% of patients and 98.57% of controls had a heterozygous deletion (TTTC/-). Concerning rs80358086, 8.57% of the patients had a heterozygous mutation (A/G) with no significantly risk association with occurrence of breast cancer (OR = 6.46; 95% CI: 0.75-55.21; p = 0.11). In addition, this heterozygous mutation was significantly associated with a family history of breast cancer (OR=128; 95% CI: 9.46-1730.93) and breast cancer risk in nonmultiparous women (OR=6; 95% CI: 1-35.90; p= 0.05) but no association with overweight/obesity (OR=1.66; 95% CI: 0.18-15.35; p=1). Conclusion This study shows high frequencies of heterozygous mutation of rs80357867 and rs80358086 from patients. In Burkina Faso, these results could help with early diagnosis of breast cancer in patients.
Collapse
Affiliation(s)
- Isabelle T Kiendrebeogo
- Laboratory of Molecular Biology and Genetics, UFR/SVT, University Joseph KI-ZERBO, Burkina Faso
- Pietro Annigoni Biomolecular Research Center, Burkina Faso
| | - Abdou A Zoure
- Laboratory of Molecular Biology and Genetics, UFR/SVT, University Joseph KI-ZERBO, Burkina Faso
- Institute of Health Sciences Research, Department of Biomedical and Public Health, Burkina Faso
| | - Fabienne I Zongo
- Laboratory of Molecular Biology and Genetics, UFR/SVT, University Joseph KI-ZERBO, Burkina Faso
| | - Serge Y Ouedraogo
- Laboratory of Molecular Biology and Genetics, UFR/SVT, University Joseph KI-ZERBO, Burkina Faso
- Pietro Annigoni Biomolecular Research Center, Burkina Faso
| | - Alexis Y Sawadogo
- Service of Gynecology, University Hospital Center Bogodogo, University Joseph KI-ZERBO, UFR/SDS, Burkina Faso
| | - Jospin Amegnona
- Laboratory of Molecular Biology and Genetics, UFR/SVT, University Joseph KI-ZERBO, Burkina Faso
| | - Herman K Sombie
- Laboratory of Molecular Biology and Genetics, UFR/SVT, University Joseph KI-ZERBO, Burkina Faso
- Pietro Annigoni Biomolecular Research Center, Burkina Faso
| | - Jean T Valérie Elvira Bazie
- Laboratory of Molecular Biology and Genetics, UFR/SVT, University Joseph KI-ZERBO, Burkina Faso
- Pietro Annigoni Biomolecular Research Center, Burkina Faso
| | - Pegdwendé A Sorgho
- Laboratory of Molecular Biology and Genetics, UFR/SVT, University Joseph KI-ZERBO, Burkina Faso
- Pietro Annigoni Biomolecular Research Center, Burkina Faso
| | - Albert T Yonli
- Laboratory of Molecular Biology and Genetics, UFR/SVT, University Joseph KI-ZERBO, Burkina Faso
- Pietro Annigoni Biomolecular Research Center, Burkina Faso
| | - Marie N Lamoussa Ouedraogo
- Laboratory of Molecular Biology and Genetics, UFR/SVT, University Joseph KI-ZERBO, Burkina Faso
- Faculty of Health Sciences, University Saint Thomas d'Aquin
| | - Dorcas Obiri-Yeboah
- Department of Microbiology and Immunology, School of Medical Sciences, University of Cape Coast
| | - Nayi Zongo
- Department of General and Digestive Surgery, University Hospital Center Yalgado Ouedraogo, University Joseph KI-ZERBO, UFR/SDS, Burkina Faso
| | - Hierrhum A Bambara
- Service of oncology, University Hospital Center Bogodogo, University Joseph KI-ZERBO, UFR/SDS, Burkina Faso
| | - Jacques Simpore
- Laboratory of Molecular Biology and Genetics, UFR/SVT, University Joseph KI-ZERBO, Burkina Faso
- Pietro Annigoni Biomolecular Research Center, Burkina Faso
- Faculty of Health Sciences, University Saint Thomas d'Aquin
| |
Collapse
|
3
|
Ouedraogo SY, Zoure AA, Zeye MMJ, Kiendrebeogo TI, Zhou X, Sawadogo AY, Simpore J, Chen H. BRCA1, BRCA2, TP53, PIK3CA, PTEN and AKT1 genes mutations in Burkina Faso breast cancer patients: prevalence, spectrum and novel variant. Mol Genet Genomics 2022; 297:1257-1268. [PMID: 35731312 DOI: 10.1007/s00438-022-01914-1] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/02/2022] [Accepted: 05/31/2022] [Indexed: 02/06/2023]
Abstract
BRCA1 and BRCA2 are the two most commonly mutated tumor suppressor genes associated with hereditary breast cancer (BC). Also, mutations in TP53, PIK3CA, PTEN and AKT1 were observed at a high frequency in BC with their mutation spectrum exhibiting a subgroup particularity with enormous clinical significance in the prevention, classification and treatment of cancers. Unfortunately, the mutation spectrum of these genes is still unknown in most Sub-Saharan African population. Therefore, using samples from 133 unselected BC patients, we aimed to assess the contribution of these mutations by direct Sanger sequencing. The analysis revealed pathogenic germline variants on BRCA1 exon 11 (c.3331C > T, 0.75%) and BRCA2 exon 11 (c.5635G > T, c.6211delA; 1.5%). Five other pathogenic variants were identified in 61 of the 133 subjects (45.86%), with 39.09% for PIK3CA, 12.78% for TP53. Interestingly, a variant in PIK3CA found in high frequency in our population was different from the one usually found in other populations (c.1634A > C, 38.34%), and four patients carried mutations linked to Cowen Syndrome 5 c.[1634A > C;1658_1659delGTinsC]. A novel variant (c.312G > T) was found in TP53 gene at 12.78%. Overall, mutation carriers were found more in Her2 negative and in patients that underwent surgery and chemotherapy. No pathogenic variant was found in PTEN and AKT1. Our population displayed a high frequency of PIK3CA mutations with an unusual distribution and spectrum as well as a relatively low prevalence of BRCA mutations. Our results provided novel data on an unstudied population and may help in prevention, and the establishment of suitable therapeutic approaches for our population.
Collapse
Affiliation(s)
- Serge Yannick Ouedraogo
- Department of Biochemistry and Molecular Biology, School of Life Sciences, Central South University, No. 172 Tongzipo Road, Changsha, 410013, Hunan, China.,Biomolecular Research Center Pietro Annigoni (CERBA)/LABIOGENE, University of Ouaga 1 Pr Joseph KI ZERBO, UFR/SVT, Ouagadougou, Burkina Faso
| | - Abdou Azaque Zoure
- Biomolecular Research Center Pietro Annigoni (CERBA)/LABIOGENE, University of Ouaga 1 Pr Joseph KI ZERBO, UFR/SVT, Ouagadougou, Burkina Faso.,Institute of Health Sciences Research (IRSS/CNRST)/Department of Biomedical and Public Health, Ouagadougou, Burkina Faso
| | - Moutanou Modeste Judes Zeye
- Biomolecular Research Center Pietro Annigoni (CERBA)/LABIOGENE, University of Ouaga 1 Pr Joseph KI ZERBO, UFR/SVT, Ouagadougou, Burkina Faso.,Department of Forensic Medicine, School of Basic Medical Sciences, Central South University, No. 172 Tongzipo Road, Changsha, 410013, Hunan, China
| | | | - Xi Zhou
- Department of Biochemistry and Molecular Biology, School of Life Sciences, Central South University, No. 172 Tongzipo Road, Changsha, 410013, Hunan, China
| | - Alexis Yobi Sawadogo
- Service of Gynecology, University Hospital Yalgado Ouédraogo, Ouagadougou, Burkina Faso
| | - Jacques Simpore
- Biomolecular Research Center Pietro Annigoni (CERBA)/LABIOGENE, University of Ouaga 1 Pr Joseph KI ZERBO, UFR/SVT, Ouagadougou, Burkina Faso
| | - Hanchun Chen
- Department of Biochemistry and Molecular Biology, School of Life Sciences, Central South University, No. 172 Tongzipo Road, Changsha, 410013, Hunan, China.
| |
Collapse
|
4
|
Diop JPD, Sène ARG, Dia Y, Ba SA, Mbacke SS, Ly CAT, Sarr PD, Diouf D, Ka S, Mbengue B, Gueye SMK, Diop PS, Sylla Niang M, Gueye PM, Lopez Sall P, Dem A, Cisse A, Dieye A, Ndiaye R. New Insights Into c.815_824dup Pathogenic Variant of BRCA1 in Inherited Breast Cancer: A Founder Mutation of West African Origin. Front Oncol 2022; 11:810060. [PMID: 35096615 PMCID: PMC8793276 DOI: 10.3389/fonc.2021.810060] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/05/2021] [Accepted: 12/07/2021] [Indexed: 11/14/2022] Open
Abstract
Founder mutations have been reported in BRCA1 and BCRA2 in different ethnic groups with inherited breast cancer. Testing of targeted mutations in specific populations is important for cancer prevention in mutation carriers. In Sub-Saharan Africa, only a few studies have reported specific founder mutations in inherited breast cancer. The pathogenic variant c.815_824dup of BRCA1 has been reported as the most frequent among African American populations with inherited breast cancer and was supposed to have a West African origin. Recent report from Senegal identified this variant in women with inherited breast cancer at the highest frequency ever reported. The variant was linked to a common haplotype confirming its founder effect in West Africa. In this article, we review the mutation history of c.815_824dup and discuss how it spread out of Africa through the transatlantic slave trade.
Collapse
Affiliation(s)
- Jean Pascal Demba Diop
- Division of Human Genetics, Faculty of Medicine, Pharmacy and Odontology, University Cheikh Anta Diop (UCAD), Dakar, Senegal
| | - Andréa Régina Gnilane Sène
- Division of Human Genetics, Faculty of Medicine, Pharmacy and Odontology, University Cheikh Anta Diop (UCAD), Dakar, Senegal
| | - Yacouba Dia
- Division of Human Genetics, Faculty of Medicine, Pharmacy and Odontology, University Cheikh Anta Diop (UCAD), Dakar, Senegal
| | - Seydi Abdoul Ba
- Division of Human Genetics, Faculty of Medicine, Pharmacy and Odontology, University Cheikh Anta Diop (UCAD), Dakar, Senegal
| | - Serigne Saliou Mbacke
- Division of Human Genetics, Faculty of Medicine, Pharmacy and Odontology, University Cheikh Anta Diop (UCAD), Dakar, Senegal
| | - Cheikh Ameth Tidiane Ly
- Division of Human Genetics, Faculty of Medicine, Pharmacy and Odontology, University Cheikh Anta Diop (UCAD), Dakar, Senegal
| | - Pierre Diaga Sarr
- Division of Human Genetics, Faculty of Medicine, Pharmacy and Odontology, University Cheikh Anta Diop (UCAD), Dakar, Senegal
| | - Doudou Diouf
- Joliot Curie Institute, Aristide Le Dantec Hospital, Dakar, Senegal
| | - Sidy Ka
- Joliot Curie Institute, Aristide Le Dantec Hospital, Dakar, Senegal
| | - Babacar Mbengue
- Immunology Unit, Faculty of Medicine, Pharmacy and Odontology, University Cheikh Anta Diop (UCAD), Dakar, Senegal
| | | | - Pape Saloum Diop
- Unit of General Surgery, General Hospital Idrissa Pouye, Dakar, Senegal
| | - Maguette Sylla Niang
- Immunology Unit, Faculty of Medicine, Pharmacy and Odontology, University Cheikh Anta Diop (UCAD), Dakar, Senegal
| | - Papa Madieye Gueye
- Laboratory of Pharmaceutical Biochemistry, Faculty of Medicine, Pharmacy and Odontology, University Cheikh Anta Diop (UCAD), Dakar, Senegal
| | - Philomene Lopez Sall
- Laboratory of Pharmaceutical Biochemistry, Faculty of Medicine, Pharmacy and Odontology, University Cheikh Anta Diop (UCAD), Dakar, Senegal
| | - Ahmadou Dem
- Joliot Curie Institute, Aristide Le Dantec Hospital, Dakar, Senegal
| | - Aynina Cisse
- Laboratory of Pharmaceutical Biochemistry, Faculty of Medicine, Pharmacy and Odontology, University Cheikh Anta Diop (UCAD), Dakar, Senegal
| | - Alioune Dieye
- Immunology Unit, Faculty of Medicine, Pharmacy and Odontology, University Cheikh Anta Diop (UCAD), Dakar, Senegal
| | - Rokhaya Ndiaye
- Division of Human Genetics, Faculty of Medicine, Pharmacy and Odontology, University Cheikh Anta Diop (UCAD), Dakar, Senegal
| |
Collapse
|
5
|
Biancolella M, Ouédraogo NLM, Zongo N, Zohoncon TM, Testa B, Rizzacasa B, Latini A, Conte C, Compaore TR, Ouedraogo CMRN, Traore SS, Simpore J, Novelli G. Breast cancer in West Africa: molecular analysis of BRCA genes in early-onset breast cancer patients in Burkina Faso. Hum Genomics 2021; 15:65. [PMID: 34717758 PMCID: PMC8557567 DOI: 10.1186/s40246-021-00365-w] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/09/2021] [Accepted: 10/17/2021] [Indexed: 01/26/2023] Open
Abstract
BACKGROUND Breast cancer (BC) is the most commonly diagnosed cancer and the second leading cause of cancer-related deaths among women in Africa after cervical cancer. Even if the epidemiological data are now aligned with those relating to industrialized countries, the knowledge concerning breast cancer in Africa, particularly in Western Africa, still lack clinical data, medical treatments, and the evaluation of genetic and non-genetic factors implicated in the etiology of the disease. The early onset and the aggressiveness of diagnosed breast cancers in patients of African ancestry strongly suggest that the genetic risk factor may be a key component, but so far, very few studies on the impact of germ line mutations in breast cancer in Africa have been conducted, with negative consequences on prevention, awareness and patient management. Through Next Generation sequencing (NGS), we analyzed all of the coding regions and the exon-intron junctions of BRCA1 and BRCA2 genes-the two most important genes in hereditary breast cancer-in fifty-one women from Burkina Faso with early onset of breast cancer with or without a family history. RESULTS We identified six different pathogenic mutations (three in BRCA1, three in BRCA2), two of which were recurrent in eight unrelated women. Furthermore, we identified, in four other patients, two variants of uncertain clinical significance (VUS) and two variants never previously described in literature, although one of them is present in the dbSNP database. CONCLUSIONS This is the first study in which the entire coding sequence of BRCA genes has been analyzed through Next Generation Sequencing in Burkinabe young women with breast cancer. Our data support the importance of genetic risk factors in the etiology of breast cancer in this population and suggest the necessity to improve the genetic cancer risk assessment. Furthermore, the identification of the most frequent mutations of BRCA1 and BRCA2 in the population of Burkina Faso will allow the development of an inexpensive genetic test for the identification of subjects at high genetic cancer risk, which could be used to design personalized therapeutic protocols.
Collapse
Affiliation(s)
- Michela Biancolella
- Department of Biology, University of Rome “Tor Vergata”, 00133 Rome, Italy
- Medical Genetics Laboratory, Tor Vergata Hospital, Rome, Italy
| | - Nabonswindé Lamoussa Marie Ouédraogo
- University Saint Thomas d’Aquin of Ouagadougou, Saint Camille Hospital, 06 BP: 10212, Ouagadougou 06, Burkina Faso
- Research Centre (CERBA), P.O. Box 364, Ouagadougou 01, Burkina Faso
| | - Nayi Zongo
- Department of Visceral Surgery of Yalgado, Ouédraogo University Hospital (CHUYO), Joseph KI ZERBO University of Ouagadougou, Ouagadougou, Burkina Faso
| | - Théodora Mahoukèdè Zohoncon
- University Saint Thomas d’Aquin of Ouagadougou, Saint Camille Hospital, 06 BP: 10212, Ouagadougou 06, Burkina Faso
- Research Centre (CERBA), P.O. Box 364, Ouagadougou 01, Burkina Faso
| | - Barbara Testa
- Department of Biomedicine and Prevention, University of Rome “Tor Vergata”, 00133 Rome, Italy
| | - Barbara Rizzacasa
- Department of Biomedicine and Prevention, University of Rome “Tor Vergata”, 00133 Rome, Italy
| | - Andrea Latini
- Department of Biomedicine and Prevention, University of Rome “Tor Vergata”, 00133 Rome, Italy
| | - Chiara Conte
- Medical Genetics Laboratory, Tor Vergata Hospital, Rome, Italy
| | | | - Charlemagne Marie Rayang-Newendé Ouedraogo
- University Saint Thomas d’Aquin of Ouagadougou, Saint Camille Hospital, 06 BP: 10212, Ouagadougou 06, Burkina Faso
- Department of the Gynecology of Bogodogo University Hospital, Joseph KI ZERBO University of Ouagadougou, 04 BP 8201, Ouagadougou 04, Burkina Faso
| | - Si Simon Traore
- University Saint Thomas d’Aquin of Ouagadougou, Saint Camille Hospital, 06 BP: 10212, Ouagadougou 06, Burkina Faso
| | - Jacques Simpore
- University Saint Thomas d’Aquin of Ouagadougou, Saint Camille Hospital, 06 BP: 10212, Ouagadougou 06, Burkina Faso
- Research Centre (CERBA), P.O. Box 364, Ouagadougou 01, Burkina Faso
| | - Giuseppe Novelli
- Medical Genetics Laboratory, Tor Vergata Hospital, Rome, Italy
- Department of Biomedicine and Prevention, University of Rome “Tor Vergata”, 00133 Rome, Italy
- IRCCS Neuromed, Pozzilli, IS Italy
- Department of Pharmacology, School of Medicine, University of Nevada, Reno, NV 89557 USA
| |
Collapse
|
6
|
Hayat M, Chen WC, Brandenburg JT, Babb de Villiers C, Ramsay M, Mathew CG. Genetic Susceptibility to Breast Cancer in Sub-Saharan African Populations. JCO Glob Oncol 2021; 7:1462-1471. [PMID: 34623906 PMCID: PMC8509920 DOI: 10.1200/go.21.00089] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/10/2021] [Revised: 07/28/2021] [Accepted: 09/01/2021] [Indexed: 12/24/2022] Open
Affiliation(s)
- Mahtaab Hayat
- Sydney Brenner Institute for Molecular Bioscience, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
- Division of Human Genetics, National Health Laboratory Service and School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
| | - Wenlong Carl Chen
- Sydney Brenner Institute for Molecular Bioscience, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
- National Cancer Registry, National Health Laboratory Service, Johannesburg, South Africa
- Non-communicable Diseases Research Division, Wits Health Consortium (PTY) Ltd, Johannesburg, South Africa
| | - Jean-Tristan Brandenburg
- Sydney Brenner Institute for Molecular Bioscience, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
| | - Chantal Babb de Villiers
- Division of Human Genetics, National Health Laboratory Service and School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
| | - Michèle Ramsay
- Sydney Brenner Institute for Molecular Bioscience, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
| | - Christopher G. Mathew
- Sydney Brenner Institute for Molecular Bioscience, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
- Division of Human Genetics, National Health Laboratory Service and School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
- Department of Medical and Molecular Genetics, Faculty of Life Sciences and Medicine, King's College London, London, United Kingdom
| |
Collapse
|
7
|
Bayala B, Zouré AA, Zohoncon TM, Tinguerie BL, Baron S, Bakri Y, Simpore J, Lobaccaro JMA. Effects of extracts and molecules derived from medicinal plants of West Africa in the prevention and treatment of gynecological cancers. A Review. Am J Cancer Res 2020; 10:2730-2741. [PMID: 33042613 PMCID: PMC7539771] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/12/2019] [Accepted: 07/19/2019] [Indexed: 06/11/2023] Open
Abstract
Medicinal plants are a potential source of drug discovery and development of new pharmacological compounds for cancer chemoprevention. More than 80% of the West African population uses medicinal plants. It is estimated that over 60% of approved anti-cancer agents are derived from plants. The plant raw material used in African traditional medicine and particularly in West Africa can be an important source for the research of anti-tumor drugs against gynecological cancers. These tumors have a negative impact on women's general health status and causes enormous health costs as they affect all age groups. Gynecological cancers remain thus a major concern worldwide, especially in West Africa where these cancers are the leading cause of cancer deaths in women. This review reports on the contribution of West African flora to the discovery of potential antiproliferative and/or cytotoxic phytochemical compounds against gynecological cancer cells. Scientific databases such as PubMed, ScienceDirect, Scopus and GoogleScholar were used to extract publications reporting West African plants and/or isolated compounds used in cell models of gynecological cancers. Thresholds of cytotoxicity and modes of action of these phytochemicals have been summarized. This research can serve as a basis for taking medicinal plants into account in the management of these gynecological cancers in resource-limited countries such as those in West Africa.
Collapse
Affiliation(s)
- Bagora Bayala
- Laboratoire de Biologie Moléculaire et de Génétique (LABIOGENE), Université Joseph KI-ZERBO03 BP 7021, Ouagadougou 03, Burkina Faso
- Centre de Recherche Biomoléculaire Pietro Annigoni (CERBA)01 BP 216 Ouagadougou 01, Burkina Faso
- Laboratoire Génétique, Reproduction &Développement, UMR CNRS 6293, INSERM U1103, Université Clermont Auvergne, 28, Place Henri Dunant, BP38, and Centre de Recherche en Nutrition Humaine d’AuvergneF63001, Clermont-Ferrand, France
- Université Norbert ZONGOBP 376 Koudougou, Burkina Faso
| | - Abdou Azaque Zouré
- Laboratoire de Biologie Moléculaire et de Génétique (LABIOGENE), Université Joseph KI-ZERBO03 BP 7021, Ouagadougou 03, Burkina Faso
- Centre de Recherche Biomoléculaire Pietro Annigoni (CERBA)01 BP 216 Ouagadougou 01, Burkina Faso
- Laboratoire de Biologie des Pathologies Humaines-BioPatH. Faculté des Sciences, Université Mohammed VRabat, Maroc
- Institut de Recherche en Sciences de la Santé (IRSS/CNRST), Département Biomédical et Santé Publique 03 BP 7192 Ouagadougou 03Burkina Faso
| | - Théodora M Zohoncon
- Laboratoire de Biologie Moléculaire et de Génétique (LABIOGENE), Université Joseph KI-ZERBO03 BP 7021, Ouagadougou 03, Burkina Faso
- Centre de Recherche Biomoléculaire Pietro Annigoni (CERBA)01 BP 216 Ouagadougou 01, Burkina Faso
- Université Saint Thomas d’Aquin (USTA)06 BP: 10212 Ouagadougou 06, Burkina Faso
- Hôpital Saint Camille de Ouagadougou (HOSCO)09 BP 444 Ouagadougou 09, Burkina Faso
| | - Bienvenu L Tinguerie
- Hôpital Saint Camille de Ouagadougou (HOSCO)09 BP 444 Ouagadougou 09, Burkina Faso
| | - Silvère Baron
- Laboratoire Génétique, Reproduction &Développement, UMR CNRS 6293, INSERM U1103, Université Clermont Auvergne, 28, Place Henri Dunant, BP38, and Centre de Recherche en Nutrition Humaine d’AuvergneF63001, Clermont-Ferrand, France
| | - Youssef Bakri
- Université Norbert ZONGOBP 376 Koudougou, Burkina Faso
| | - Jacques Simpore
- Laboratoire de Biologie Moléculaire et de Génétique (LABIOGENE), Université Joseph KI-ZERBO03 BP 7021, Ouagadougou 03, Burkina Faso
- Centre de Recherche Biomoléculaire Pietro Annigoni (CERBA)01 BP 216 Ouagadougou 01, Burkina Faso
- Université Saint Thomas d’Aquin (USTA)06 BP: 10212 Ouagadougou 06, Burkina Faso
- Hôpital Saint Camille de Ouagadougou (HOSCO)09 BP 444 Ouagadougou 09, Burkina Faso
| | - Jean-Marc A Lobaccaro
- Laboratoire Génétique, Reproduction &Développement, UMR CNRS 6293, INSERM U1103, Université Clermont Auvergne, 28, Place Henri Dunant, BP38, and Centre de Recherche en Nutrition Humaine d’AuvergneF63001, Clermont-Ferrand, France
| |
Collapse
|
8
|
El Ansari FZ, Jouali F, Marchoudi N, Bennani MM, Ghailani NN, Barakat A, Fekkak J. Screening of BRCA1/2 genes mutations and copy number variations in patients with high risk for hereditary breast and ovarian cancer syndrome (HBOC). BMC Cancer 2020; 20:747. [PMID: 32778078 PMCID: PMC7418307 DOI: 10.1186/s12885-020-07250-0] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/02/2020] [Accepted: 08/03/2020] [Indexed: 12/12/2022] Open
Abstract
Background Hereditary breast and ovarian cancer (HBOC) is an autosomal dominant inherited cancer susceptibility disorder. Both BRCA1 and BRCA2 genes are considered as high penetrance genes of this syndrome. The identification of BRCA1/2 genetic alterations before cancer development, grant patients the chance to benefit from various medical cancer prevention approaches. Therefore, the appearance of recent advanced technologies in molecular analysis such as next generation sequencing has simplified full BRCA1/2 analysis. Many attempts took place in hope of understanding the molecular germline spectrum of these two genes in Moroccan HBOC patients. However, most of the past projects focused only on young breast cancer cases, lacked ovarian cancer cases in their cohort and only a limited number of these studies were able to analyze the entire exons or copy number variations for both genes. In attempt of gaining more information regarding the molecular profile of BRCA1/2 in HBOC, we conducted a study in which we analyze their molecular profile on selected Moroccan patients suspected of having HBOC syndrome. Methods In this study we obtained blood samples from 64 selected Moroccan patients, who suffered from Breast and/or ovarian cancer and had a strong family history for cancer. To analyze BRCA1/2 punctual variants and copy number variations, we used the Ion Personal Genome Machine (PGM) and Oncomine BRCA1/2 research assay panel. Afterward, we correlated the molecular results with the clinic-pathologic data using IBM SPSS Statistics ver 2. Results From the 64 selected cases, Forty-six had breast cancer, fifteen had ovarian cancer and three had both breast and ovarian cancer. The molecular analysis revealed that 18 patients from the 64 harbored a pathogenic variant (28%). Twelve had six different BRCA1 pathogenic variants and six had six different BRCA2 pathogenic variants. In this study, we report four pathogenic variants that to the best of our knowledge has never been reported in the Moroccan population before. Regarding copy number variation analysis, No CNV was detected in both genes for all the 64 successfully sequenced and analyzed patients in our cohort. Conclusion Work like the present has an important implication on public health and science. It is critical that molecular profiling studies are performed on underserved and understudied population like Morocco.
Collapse
Affiliation(s)
- Fatima Zahra El Ansari
- Biomedical Genomics and Oncogenetics Research Laboratory, Faculty of Sciences and Techniques of Tangier, University Abdelmalek Essaâdi, 90000, Tangier, Morocco. .,Molecular Biology Department, ANOUAL Laboratory, Casablanca, Morocco.
| | - Farah Jouali
- Molecular Biology Department, ANOUAL Laboratory, Casablanca, Morocco
| | - Nabila Marchoudi
- Molecular Biology Department, ANOUAL Laboratory, Casablanca, Morocco
| | - Mohcine Mechita Bennani
- Biomedical Genomics and Oncogenetics Research Laboratory, Faculty of Sciences and Techniques of Tangier, University Abdelmalek Essaâdi, 90000, Tangier, Morocco
| | - Naima Nourouti Ghailani
- Biomedical Genomics and Oncogenetics Research Laboratory, Faculty of Sciences and Techniques of Tangier, University Abdelmalek Essaâdi, 90000, Tangier, Morocco
| | - Amina Barakat
- Biomedical Genomics and Oncogenetics Research Laboratory, Faculty of Sciences and Techniques of Tangier, University Abdelmalek Essaâdi, 90000, Tangier, Morocco
| | - Jamal Fekkak
- Molecular Biology Department, ANOUAL Laboratory, Casablanca, Morocco
| |
Collapse
|
9
|
Evidence for an ancient BRCA1 pathogenic variant in inherited breast cancer patients from Senegal. NPJ Genom Med 2020; 5:8. [PMID: 32025337 PMCID: PMC6994613 DOI: 10.1038/s41525-020-0114-7] [Citation(s) in RCA: 12] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/17/2019] [Accepted: 01/02/2020] [Indexed: 12/13/2022] Open
Abstract
BRCA1 and BRCA2 are the most incriminated genes in inherited breast/ovarian cancers. Several pathogenic variants of these genes conferring genetic predisposition have been described in different populations but rarely in sub-Saharan Africa. The objectives of this study were to identify pathogenic variants of the BRCA genes involved in hereditary breast cancer in Senegal and to search for a founder effect. We recruited after free informed consent, 27 unrelated index cases diagnosed with breast cancer and each having a family history. Mutation screening of the genes identified a duplication of ten nucleotides c.815_824dupAGCCATGTGG, (p.Thr276Alafs) (NM_007294.3) located in exon 11 of BRCA1 gene, in 15 index cases (allelic frequency 27.7%). The pathogenic variant has been previously reported in African Americans as a founder mutation of West African origin. Haplotypes analysis of seven microsatellites surrounding the BRCA1 gene highlights a shared haplotype encompassing ~400 kb between D17S855 and D17S1325. This haplotype was not detected in none of 15 healthy controls. Estimation of the age of the pathogenic variant suggested that it occurred ~1400 years ago. Our study identified a founder pathogenic variant of BRCA1 predisposing to breast cancer and enabled the establishment of an affordable genetic test as a mean of prevention for Senegalese women at risk.
Collapse
|
10
|
Friebel TM, Andrulis IL, Balmaña J, Blanco AM, Couch FJ, Daly MB, Domchek SM, Easton DF, Foulkes WD, Ganz PA, Garber J, Glendon G, Greene MH, Hulick PJ, Isaacs C, Jankowitz RC, Karlan BY, Kirk J, Kwong A, Lee A, Lesueur F, Lu KH, Nathanson KL, Neuhausen SL, Offit K, Palmero EI, Sharma P, Tischkowitz M, Toland AE, Tung N, van Rensburg EJ, Vega A, Weitzel JN, Hoskins KF, Maga T, Parsons MT, McGuffog L, Antoniou AC, Chenevix-Trench G, Huo D, Olopade OI, Rebbeck TR. BRCA1 and BRCA2 pathogenic sequence variants in women of African origin or ancestry. Hum Mutat 2019; 40:1781-1796. [PMID: 31112363 PMCID: PMC6764847 DOI: 10.1002/humu.23804] [Citation(s) in RCA: 25] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/02/2019] [Revised: 03/22/2019] [Accepted: 05/07/2019] [Indexed: 01/03/2023]
Abstract
BRCA1 and BRCA2 (BRCA1/2) pathogenic sequence variants (PSVs) confer elevated risks of multiple cancers. However, most BRCA1/2 PSVs reports focus on European ancestry individuals. Knowledge of the PSV distribution in African descent individuals is poorly understood. We undertook a systematic review of the published literature and publicly available databases reporting BRCA1/2 PSVs also accessed the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA) database to identify African or African descent individuals. Using these data, we inferred which of the BRCA PSVs were likely to be of African continental origin. Of the 43,817 BRCA1/2 PSV carriers in the CIMBA database, 469 (1%) were of African descent. Additional African descent individuals were identified in public databases (n = 291) and the literature (n = 601). We identified 164 unique BRCA1 and 173 unique BRCA2 PSVs in individuals of African ancestry. Of these, 83 BRCA1 and 91 BRCA2 PSVs are of likely or possible African origin. We observed numerous differences in the distribution of PSV type and function in African origin versus non-African origin PSVs. Research in populations of African ancestry with BRCA1/2 PSVs is needed to provide the information needed for clinical management and decision-making in African descent individuals worldwide.
Collapse
Affiliation(s)
- Tara M. Friebel
- Harvard T.H. Chan School of Public Health. Boston, MA: USA; 02115
- Dana-Farber Cancer Institute. Boston, MA: USA; 02215
| | - Irene L. Andrulis
- Fred A. Litwin Center for Cancer Genetics. Lunenfeld-Tanenbaum Research Institute of Mount Sinai Hospital. Toronto, ON: Canada; M5G 1X5
- Department of Molecular Genetics. University of Toronto. Toronto, ON: Canada; M5S 1A8
| | - Judith Balmaña
- High Risk and Cancer Prevention Group. Vall dHebron Institute of Oncology, University Hospital Vall dHebron. Barcelona: Spain; 08035
| | - Amie M. Blanco
- Cancer Genetics and Prevention Program. University of California San Francisco. San Francisco, CA: USA; 94143-1714
| | - Fergus J. Couch
- Department of Laboratory Medicine and Pathology. Mayo Clinic. Rochester, MN: USA; 55905
| | - Mary B. Daly
- Department of Clinical Genetics. Fox Chase Cancer Center. Philadelphia, PA: USA; 19111
| | - Susan M. Domchek
- Department of Medicine, Abramson Cancer Center. Perelman School of Medicine at the University of Pennsylvania. Philadelphia, PA: USA; 19104
| | - Douglas F. Easton
- Centre for Cancer Genetic Epidemiology, Department of Oncology. University of Cambridge. Cambridge: UK; CB1 8RN
- Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care. University of Cambridge. Cambridge: UK; CB1 8RN
| | - William D. Foulkes
- Program in Cancer Genetics, Departments of Human Genetics and Oncology. McGill University. Montréal, QC: Canada; H4A 3J1
| | - Patricia A. Ganz
- Schools of Medicine and Public Health, Division of Cancer Prevention & Control Research. Jonsson Comprehensive Cancer Centre, UCLA. Los Angeles, CA: USA; 90096-6900
| | - Judy Garber
- Cancer Risk and Prevention Clinic. Dana-Farber Cancer Institute. Boston, MA: USA; 02215
| | - Gord Glendon
- Fred A. Litwin Center for Cancer Genetics. Lunenfeld-Tanenbaum Research Institute of Mount Sinai Hospital. Toronto, ON: Canada; M5G 1X5
| | - Mark H. Greene
- Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics. National Cancer Institute. Bethesda, MD: USA; 20850-9772
| | - Peter J. Hulick
- Center for Medical Genetics. NorthShore University HealthSystem. Evanston, IL: USA; 60201
- The University of Chicago Pritzker School of Medicine. Chicago, IL: USA; 60637
| | - Claudine Isaacs
- Lombardi Comprehensive Cancer Center, Georgetown University. Washington, DC: USA; 20007
| | - Rachel C. Jankowitz
- Department of Medicine, Division of Hematology/Oncology. UPMC Hillman Cancer Center; University of Pittsburgh School of Medicine. Pittsburgh: USA; PA 15232
| | - Beth Y. Karlan
- Womens Cancer Program at the Samuel Oschin Comprehensive Cancer Institute. Cedars-Sinai Medical Center. Los Angeles, CA: USA; 90048
| | - Judy Kirk
- Familial Cancer Service. Weatmead Hospital. Vol P.O. Box 533. Wentworthville, New South Wales: Australia; 2145
| | - Ava Kwong
- Hong Kong Hereditary Breast Cancer Family Registry. Cancer Genetics Centre. Happy Valley: Hong Kong
- Department of Surgery. The University of Hong Kong. Pok Fu Lam: Hong Kong
- Department of Surgery. Hong Kong Sanatorium and Hospital. Happy Valley: Hong Kong
| | - Annette Lee
- The Feinstein Institute for Medical Research. Manhasset, NY: USA; 11030
| | - Fabienne Lesueur
- Genetic Epidemiology of Cancer team. Inserm U900. Paris: France; 75005
- Service de Génétique. Institut Curie. Paris: France; 75005
- Institut Curie. Paris: France; 75005
- Mines ParisTech. Fontainebleau: France; 77305
| | - Karen H. Lu
- Department of Gynecologic Oncology and Clinical Cancer Genetics Program. University of Texas MD Anderson Cancer Center. Houston, TX: USA; 77030
| | - Katherine L. Nathanson
- Department of Medicine, Abramson Cancer Center. Perelman School of Medicine at the University of Pennsylvania. Philadelphia, PA: USA; 19104
| | - Susan L. Neuhausen
- Department of Population Sciences. Beckman Research Institute of City of Hope. Duarte, CA: USA; 91010
| | - Kenneth Offit
- Clinical Genetics Research Lab, Department of Cancer Biology and Genetics. Memorial Sloan-Kettering Cancer Center. New York, NY: USA; 10065
- Clinical Genetics Service, Department of Medicine. Memorial Sloan-Kettering Cancer Center. New York, NY: USA; 10065
| | - Edenir I. Palmero
- Molecular Oncology Research Center. Barretos Cancer Hospital. São Paulo: Brazil; 784-400
- Barretos School of Health Sciences, Dr. Paulo Prata - FACISB. São Paulo: Brazil; 785-002
| | - Priyanka Sharma
- Department of Internal Medicine, Division of Oncology. University of Kansas Medical Center. Westwood, KS: USA; 66205
| | - Marc Tischkowitz
- Program in Cancer Genetics, Departments of Human Genetics and Oncology. McGill University. Montréal, QC: Canada; H4A 3J1
- Department of Medical Genetics. University of Cambridge. Vol Box 134, Level 6 Addenbrookes Treatment Centre, Addenbrookes Hosptital. Cambridge: UK; CB2 0QQ
| | - Amanda E. Toland
- Department of Cancer Biology and Genetics. The Ohio State University. Columbus, OH: USA; 43210
| | - Nadine Tung
- Department of Medical Oncology. Beth Israel Deaconess Medical Center. Boston, MA: USA; 02215
| | | | - Ana Vega
- Fundación Pública Galega Medicina Xenómica. Santiago De Compostela: Spain; 15706
- Instituto de Investigación Sanitaria de Santiago de Compostela. Santiago De Compostela: Spain; 15706
- Biomedical Network on Rare Diseases (CIBERER). Madrid: Spain; 28029
| | | | | | - Kent F. Hoskins
- Department of Medicine. University of Illinois. Chicago, IL: USA
| | - Tara Maga
- Department of Medicine. University of Illinois. Chicago, IL: USA
| | - Michael T. Parsons
- Department of Genetics and Computational Biology. QIMR Berghofer Medical Research Institute. Vol Locked Bag 2000, Herston, QLD 4029. Brisbane, Queensland: Australia; 4006
| | - Lesley McGuffog
- Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care. University of Cambridge. Cambridge: UK; CB1 8RN
| | - Antonis C. Antoniou
- Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care. University of Cambridge. Cambridge: UK; CB1 8RN
| | - Georgia Chenevix-Trench
- Department of Genetics and Computational Biology. QIMR Berghofer Medical Research Institute. Vol Locked Bag 2000, Herston, QLD 4029. Brisbane, Queensland: Australia; 4006
| | - Dezheng Huo
- Center for Clinical Cancer Genetics. The University of Chicago. Chicago, IL: USA; 60637
| | | | - Timothy R. Rebbeck
- Harvard T.H. Chan School of Public Health. Boston, MA: USA; 02115
- Dana-Farber Cancer Institute. Boston, MA: USA; 02215
| |
Collapse
|